Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 5/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL864571 | 1.00 | MAP4K4 (0.51) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL864932 | 0.88 | MAP4K4 (0.51) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL864931 | 0.88 | MAP4K4 (0.51) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL864327 | 0.87 | MAP4K4 (0.46) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL864328 | 0.87 | MAP4K4 (0.46) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL864458 | 0.85 | MAP4K4 (0.44) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL864459 | 0.85 | MAP4K4 (0.44) | MAP4K4EGFRKDRPIK3CDAAK1 | |
| SCHEMBL865004 | 0.80 | MAP4K4 (0.39) | MAP4K4PIK3CDIRAK4PIK3R2 | |
| SCHEMBL865005 | 0.80 | MAP4K4 (0.39) | MAP4K4PIK3CDIRAK4PIK3R2 | |
| SCHEMBL14482960 | 0.80 | MAP4K4 (0.42) | MAP4K4EGFRKDRPIK3CDAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396315-B1 | QUINOLINE DERIVATIVES AS PI3K KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-08-31 | — | — | EP | disclosed |
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | MAP4K4 34/4885EGFR 3185/4885KDR 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.